Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Hematologic Diseases 1

Interventions

Cyclophosphamide 34fludarabine phosphate 33Cytarabine 33fludarabine 26Peripheral Blood Stem Cell Transplantation 23Filgrastim 23Methotrexate 18Busulfan 17Rituximab 15Cyclosporine 14Azacitidine 14Melphalan 13Clofarabine 13Tacrolimus 12venetoclax 11Mycophenolic Acid 10Etoposide 10Alemtuzumab 10Radiotherapy 9Imatinib Mesylate 8Granulocyte Colony-Stimulating Factor 8Decitabine 8ruxolitinib 7Whole-Body Irradiation 7Stem Cell Transplantation 7Idarubicin 7Dexamethasone 7Antilymphocyte Serum 7aldesleukin 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia × dacetuzumab × Clear all
NCT00283101 2014-12-18

A Safety Study in Patients With Chronic Lymphocytic Leukemia

Seagen Inc.

Phase 1/2 Completed
12 enrolled
LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡